Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | DUT | P33316 | 3/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10953746 | 0.90 | CRBN (0.50) | CRBNDDB1ALDH1A1LMNADUT | |
| SCHEMBL2976955 | 0.83 | CRBN (0.48) | CRBNDDB1ALDH1A1LMNADUT | |
| SCHEMBL28132697 | 0.82 | CRBN (0.47) | CRBNDDB1ALDH1A1LMNADUT | |
| SCHEMBL27581645 | 0.81 | CRBN (0.50) | CRBNDDB1ALDH1A1LMNADUT | |
| SCHEMBL5353434 | 0.79 | CRBN (0.46) | CRBNDDB1ALDH1A1LMNADUT | |
| SCHEMBL4755093 | 0.78 | CRBN (0.52) | CRBNDDB1ALDH1A1LMNADUT | |
| SCHEMBL7056290 | 0.78 | CRBN (0.52) | CRBNDDB1ALDH1A1LMNADUT | |
| SCHEMBL913153 | 0.76 | TYMP (0.51) | CRBNDDB1LMNADUTPKM | |
| SCHEMBL17371854 | 0.73 | CRBN (0.47) | CRBNDDB1ALDH1A1LMNADUT | |
| SCHEMBL1526612 | 0.73 | CRBN (0.47) | CRBNDDB1ALDH1A1LMNADUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230148152-A1 | METHOD OF SYNTHESIZING SINGLE-STRANDED NUCLEOTIDE SEQUENCE, BLOCKED NUCLEOSIDE TRIPHOSPHATES AND RELATED METHODS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-05-11 | — | — | US | claimed |
| US-9677067-B2 | Compositions and methods for synthetic gene assembly | Twist Bioscience Corporation (US) | 2017-06-13 | — | — | US | claimed |
| US-20170159044-A1 | COMPOSITIONS AND METHODS FOR SYNTHETIC GENE ASSEMBLY | Twist Bioscience Corporation | 2017-06-08 | — | — | US | claimed |
| US-20160264958-A1 | COMPOSITIONS AND METHODS FOR SYNTHETIC GENE ASSEMBLY | Twist Bioscience Corporation | 2016-09-15 | — | — | US | claimed |
| WO-2016126987-A1 | COMPOSITIONS AND METHODS FOR SYNTHETIC GENE ASSEMBLY | Twist Bioscience Corporation (US) | 2016-08-11 | — | — | WO | claimed |
| US-20240166683-A1 | CHEMICAL TOOLS FOR RNA 3D STRUCTURE DETERMINATION IN VIVO | UNIV SOUTHERN CALIFORNIA (US) | 2024-05-23 | — | — | US | disclosed |
| US-20240150830-A1 | PHASED GENOME SCALE EPIGENETIC MAPS AND METHODS FOR GENERATING MAPS | THE BROAD INSTITUTE, INC. | 2024-05-09 | — | — | US | disclosed |
| US-20240125797-A1 | QUANTIFICATION OF CELLULAR PROTEINS USING BARCODED BINDING MOIETIES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2024-04-18 | — | — | US | disclosed |
| EP-4339298-A2 | HIGH EFFICIENCY TARGETED IN SITU GENOME-WIDE PROFILING | Fred Hutchinson Cancer Center (US) | 2024-03-20 | — | — | EP | disclosed |
| US-11898141-B2 | High-throughput assembly of genetic elements | THE BROAD INSTITUTE, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-11885814-B2 | High efficiency targeted in situ genome-wide profiling | FRED HUTCHINSON CANCER CENTER (US) | 2024-01-30 | — | — | US | disclosed |
| US-11873483-B2 | Proteomic analysis with nucleic acid identifiers | THE BROAD INSTITUTE, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20030023991-A1 | Hypohidrotic ectodermal dysplasia genes and proteins | BAYLOR COLLEGE OF MEDICINE | 2003-01-30 | — | — | US | disclosed |
| US-20030017985-A1 | Molecules that influence pathogen resistance | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARMENT OF HEALTH AND HUMAN SERVICES | 2003-01-23 | — | — | US | disclosed |
| WO-2002081632-A2 | NUCLEIC ACIDS FOR TRANSGENE EXPRESSION | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2002056668-A2 | METHODS TO CONTROL THE HOST RANGE OF RETROVIRAL VECTORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002027014-A2 | DETECTION OF FECAL CONTAMINATION | THE STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON STATE UNIVERSITY (US) | 2002-04-04 | — | — | WO | disclosed |
| EP-1117778-A2 | METHODS AND COMPOSITIONS FOR INDUCING DIFFERENTIATION AND APOPTOSIS IN CELLS THAT OVEREXPRESS THE NOTCH PROTEIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-07-25 | — | — | EP | disclosed |
| WO-2001034177-A2 | METHOD OF TREATING A VIRAL INFECTION USING ANTAGONISTS OF MACROPHAGE COLONY STIMULATING FACTOR | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, A S REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEA LTH & HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2000020576-A2 | METHODS AND COMPOSITIONS FOR INDUCING DIFFERENTIATION AND APOTOSIS IN CELLS THAT OVEREXPESS THE NOTCH PROTEIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH (US) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166683-A1 | CHEMICAL TOOLS FOR RNA 3D STRUCTURE DETERMINATION IN VIVO | NSUN3, NSUN2, HNRNPC | CRBN 3346/4885DDB1 1164/4885ALDH1A1 1193/4885 |
| US-20230148152-A1 | METHOD OF SYNTHESIZING SINGLE-STRANDED NUCLEOTIDE SEQUENCE, BLOCKED NUCLEOSIDE TRIPHOSPHATES AND RELATED METHODS | RNGTT, NT5C3B, TYMP | CRBN 4105/4885DDB1 437/4885ALDH1A1 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.